Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–258 of 258 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ACTOS/pioglitazone Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone

NCT01395784
View directory record Official record
Conditions
Opioid Abuse
Interventions
pioglitazone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Study of NGM313 in Obese Participants

NCT03298464
View directory record Official record
Conditions
Obese
Interventions
NGM313, Pioglitazone
Biological · Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Pioglitazone

NCT04671056
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Pioglitazone 15mg
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

NCT00554853
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
pioglitazone, Sublingual nitroglycerine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Integrating the Genetic and Metabolic Faces of Obesity

NCT00285844
View directory record Official record
Conditions
Insulin Resistance, Obesity, Metabolic Syndrome
Interventions
weight loss, thiazolidinedione
Behavioral · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanisms Underlying Metabolic Syndrome in Obesity

NCT00579813
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance, Prediabetes
Interventions
Pioglitazone
Drug
Lead sponsor
Philip Kern
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Little Rock, Arkansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 17, 2026, 5:57 PM EDT
Withdrawn Phase 3 Interventional

Pioglitazone and Insulin Resistance in ADT

NCT05098327
View directory record Official record
Conditions
Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2, Androgen Deficiency
Interventions
Pioglitazone 30 mg, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

NCT00328627
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Alogliptin, Alogliptin placebo, Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
72
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Not applicable Interventional Results available

Pioglitazone on Pancreatic Steatosis and Bone Health

NCT00855010
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
pioglitazone, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

NCT03231033
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Pioglitazone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 3 Interventional

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

NCT00106808
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Muraglitazar, Pioglitazone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
112
States / cities
Birmingham, Alabama • Columbiana, Alabama • Madison, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Not applicable Interventional Results available

Pioglitazone for the Treatment of Alcohol Use Disorder

NCT03864146
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Brief Behavioral Compliance Enhancement Treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Long Beach, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

NCT00637273
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Peoria, Arizona • Artesia, California • Concord, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women

NCT01748994
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 17, 2026, 5:57 PM EDT
Recruiting Phase 1 Interventional

Prevention of Progression of Prediabetes, Obesity and CV Risk

NCT06446531
View directory record Official record
Conditions
Pre-Diabetes, Weight, Body, Cardiovascular Diseases
Interventions
Placebo, Rybelsus Tablet, Jardiance 25Mg Tablet, Metformin, Actos
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Results available

Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?

NCT01040819
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 17, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

NCT00996658
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 79 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
29
States / cities
Escondido, California • Greenbrae, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 17, 2026, 5:57 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

NCT05838287
View directory record Official record
Conditions
Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 5:57 PM EDT